glaucoma: Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
111 |
4. Check minimum number of eventsNone |
111 |
5. Include endpointsNone |
111 |
6. Filter based on genotype QC (FinnGen only) |
111 |
Control definitions (FinnGen only)
- Control exclude
- H7_GLAUCOMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H40
- Name in latin
- Glaucoma ex usu medicamenti
Similar endpoints
↥List of similar endpoints to
Glaucoma secondary to drugs
based on the number of shared cases.
Similar with more cases:
- Glaucoma
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 667 | 340 | 320 |
| Only index persons | 593 | 307 | 286 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.35 | 54.38 | 54.37 |
| Only index persons | 52.80 | 52.63 | 52.98 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 111 | 52 | 59 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 52.09 | 51.13 | 52.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 100
- Matched controls
- 1001
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H40.6
ICD-10 Finland
Glaucoma secondary to drugs
+∞
116.8
88
*
S01ED51
ATC
timolol, combinations; ophthalmic
258.3
69.8
65
7
114
Kela drug reimbursment
Glaucoma
237.0
67.0
63
7
H40.0
ICD-10 Finland
Glaucoma suspect
+∞
44.1
39
*
S01ED01
ATC
timolol; ophthalmic
163.7
40.3
40
*
S01EE01
ATC
latanoprost; ophthalmic
132.4
34.3
35
*
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
+∞
33.2
30
*
S01EA05
ATC
brimonidine; ophthalmic (sympathomimetics in glaucoma therapy)
+∞
28.5
26
*
S01EC04
ATC
brinzolamide; ophthalmic
328.9
26.0
25
*
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
35.4
25.0
32
13
S01EC01
ATC
acetazolamide; systemic
164.5
24.9
25
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
17.0
24.5
41
39
H20.1
ICD-10 Finland
Chronic iridocyclitis
147.5
22.6
23
*
Z96.1
ICD-10 Finland
Presence of intraocular lens
13.4
21.9
41
49
XCK00
NOMESCO Finland
Perimetry
46.8
21.0
25
7
H40.13
ICD-10 Finland
Chronic glaucoma with open ventricular angle
+∞
18.3
17
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
10.3
18.2
39
58
S01BA04
ATC
prednisolone; ophthalmic (corticosteroids, plain)
61.7
17.7
20
*
S01BA01
ATC
dexamethasone; ophthalmic (corticosteroids, plain)
23.8
17.0
24
13
S01EX03
ATC
NA
+∞
16.1
15
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
5.8
15.5
66
249
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.4
14.7
39
79
S01BA07
ATC
fluorometholone; ophthalmic (corticosteroids, plain)
40.4
14.0
17
5
S01EE05
ATC
tafluprost; ophthalmic
40.4
14.0
17
5
3653A
ICD-9 Finland
Glaucoma, Corticosteroid-induced glaucoma
+∞
13.9
13
*
H26.3
ICD-10 Finland
Drug-induced cataract
80.4
12.9
14
*
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
5.1
12.2
48
153
S01EE03
ATC
bimatoprost; ophthalmic
134.9
11.7
12
*
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
7.3
11.5
29
53
CJB10
NOMESCO Finland
Laser discission of secondary cataract
10.0
11.4
23
29
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
49.3
11.2
13
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
14.3
10.9
18
15
S01EC03
ATC
dorzolamide; ophthalmic
122.3
10.6
11
*
S01EE04
ATC
travoprost; ophthalmic
122.3
10.6
11
*
L04AX01
ATC
azathioprine; systemic
13.4
10.6
18
16
H02AB06
ATC
prednisolone; systemic
4.2
10.5
66
316
A07EC01
ATC
sulfasalazine; oral, rectal
7.3
10.5
26
46
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
8.5
10.4
23
34
XCK10
NOMESCO Finland
Photography of fundus of eye
8.0
10.4
24
38
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
4.2
10.0
50
193
S01EC54
ATC
brinzolamide, combinations; ophthalmic
61.1
9.9
11
*
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
12.5
9.7
17
16
S01ED02
ATC
betaxolol; ophthalmic
+∞
9.5
9
*
H40.4
ICD-10 Finland
Glaucoma secondary to eye inflammation
+∞
9.5
9
*
CHD05
NOMESCO Finland
Selective lasertrabeculoplasty
+∞
9.5
9
*
H26.4
ICD-10 Finland
After-cataract
7.8
9.1
21
33
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
22.4
8.7
12
6
CHD50
NOMESCO Finland
Shunt operation on anterior chamber
+∞
8.4
8
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.6
8.2
19
30
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
16.8
7.9
12
8
S01FA02
ATC
scopolamine; ophthalmic
49.0
7.8
9
*
M05BA04
ATC
alendronic acid; oral
9.6
7.6
15
18
WX140
NOMESCO Finland
Parabulbar anesthesy
9.6
7.6
15
18
CHD65
NOMESCO Finland
Nonpenetrating glaucoma surgery
+∞
7.4
7
*
S01EA02
ATC
dipivefrine; ophthalmic
+∞
7.4
7
*
S01FA01
ATC
atropine; ophthalmic
+∞
7.4
7
*
S01FA04
ATC
cyclopentolate; ophthalmic
32.6
7.3
9
*
L04AB04
ATC
adalimumab; parenteral
32.6
7.3
9
*
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
8.2
7.0
15
21
H04.10
ICD-10 Finland
Dry eye syndrome
5.0
6.9
22
53
H26.2
ICD-10 Finland
Complicated cataract
43.1
6.9
8
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.6
6.7
19
40
S01EA03
ATC
apraclonidine; ophthalmic
74.4
6.5
7
*
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
74.4
6.5
7
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
6.4
43
194
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
+∞
6.3
6
*
H40.9
ICD-10 Finland
Glaucoma, unspecified
+∞
6.3
6
*
S01EB01
ATC
pilocarpine; ophthalmic
+∞
6.3
6
*
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
13.7
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
51
4.29
6.69
3.3
1.9
40.7
41.8
u/l
0.09
19
44
70
433
2.67
5.82
10.0
6.3
1.2
1.2
mmol/l
0.11
55
366
46
273
2.17
3.73
5.5
3.8
15.2
10.1
mg/mmol
0.24
34
169
9
21
4.57
3.07
1.4
2.0
—
—
—
0
0
34
194
2.08
2.96
1.8
1.8
400.5
474.8
pmol/l
1.26
27
164
9
22
4.35
2.95
1.0
1.2
—
—
—
0
0
62
451
1.85
2.57
4.6
3.8
0.0
0.0
estimate
0.00
14
83
62
456
1.81
2.43
5.0
3.9
0.0
0.0
estimate
0.00
12
80
13
56
2.50
2.14
3.4
4.2
72.3
75.2
ng/l
0.04
13
50
28
168
1.89
2.06
1.8
1.6
1171.2
1181.4
nmol/l
0.02
22
123
60
452
1.71
2.05
6.1
5.2
0.0
0.0
estimate
0.00
14
83
7
21
3.48
2.00
1.1
1.6
—
—
—
0
0
10
39
2.72
1.98
7.4
4.4
59.1
53.6
%
—
10
39
6
16
3.90
1.96
1.8
3.0
20.7
17.0
%
—
6
7
12
52
2.47
1.95
4.3
3.0
136.1
133.9
g/l
0.10
12
52
5
12
4.31
1.84
1.4
3.2
12.6
22.6
nmol/l
—
5
12
12
55
2.33
1.74
3.6
2.8
5.2
5.1
kpa
0.09
12
50
6
20
3.11
1.60
2.8
2.2
25.2
25.8
mmol/l
—
6
15
81
686
1.67
1.58
4.6
4.0
15.0
14.8
pmol/l
0.31
74
621
8
33
2.53
1.57
4.9
3.1
—
—
—
0
0
42
308
1.58
1.48
2.3
3.4
2.3
2.4
mmol/l
0.53
37
270
36
256
1.60
1.44
3.6
2.9
991.8
988.0
ng/l
0.00
29
214
48
367
1.54
1.40
4.6
3.9
—
—
—
0
0
6
24
2.58
1.32
1.0
1.3
—
—
—
0
0
18
109
1.78
1.28
11.3
7.1
—
—
—
0
0
94
847
1.72
1.22
5.6
4.6
2.1
1.9
mu/l
0.79
84
773
35
260
1.51
1.13
5.7
2.9
0.1
0.3
e6/l
2.08
30
183
34
251
1.51
1.13
5.4
4.1
0.0
0.0
estimate
0.00
11
79
24
166
1.57
1.06
1.8
3.1
2.4
2.5
mmol/l
0.45
19
141
5
22
2.33
1.04
1.4
1.5
—
—
—
0
0
41
324
1.42
0.95
2.5
1.9
96.0
91.5
pmol/l
0.31
28
166
6
27
2.29
0.95
3.0
2.5
—
—
—
0
0
14
87
1.70
0.93
3.2
3.4
—
—
—
0
0
17
113
1.60
0.88
1.3
1.4
—
—
—
0
0
50
414
1.38
0.87
5.8
4.2
35.1
35.7
g/l
0.25
45
393
8
45
1.84
0.86
3.8
2.4
1.3
1.2
%
—
8
45
26
194
1.44
0.81
1.8
1.8
1.1
1.6
mg/l
0.38
19
163
26
194
1.44
0.81
1.7
1.5
21.1
20.6
nmol/l
0.06
21
166
0
24
0.00
0.80
0.0
1.9
—
994.7
—
0
10
5
23
2.23
0.77
2.0
1.3
—
—
—
0
0
58
499
1.34
0.77
6.2
6.9
14.5
10.7
umol/l
0.40
53
476
41
336
1.35
0.75
6.4
3.1
—
—
—
0
0
99
931
1.59
0.74
23.7
13.7
18.7
22.1
mg/l
0.54
84
719
9
57
1.63
0.73
3.2
2.9
4.8
4.6
pmol/l
—
9
47
5
26
1.97
0.71
1.8
2.1
—
—
—
0
0
5
26
1.97
0.71
3.4
1.9
185.0
175.5
%
—
5
26
7
42
1.71
0.70
1.7
1.8
—
—
—
0
0
5
28
1.82
0.67
2.4
1.4
—
—
—
0
0
93
871
1.42
0.63
17.2
12.8
81.3
82.0
ml/min/173m2
0.11
85
708
5
30
1.70
0.62
5.8
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.5
—
557.7
—
0
21
22
170
1.37
0.57
1.3
1.3
35.2
40.8
iu/ml
—
7
55
37
315
1.26
0.49
2.2
2.3
54.9
56.2
u/l
0.13
30
289
7
50
1.43
0.46
3.9
1.3
—
—
—
0
0
28
235
1.26
0.42
1.4
1.3
1.1
1.7
u/ml
—
7
60
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
9
67
1.37
0.39
2.3
1.4
—
—
—
0
0
20
164
1.27
0.36
1.2
1.2
8.0
12.5
u/ml
—
7
68
40
358
1.18
0.32
4.9
3.7
30.2
30.7
ng/l
0.01
34
236
24
278
0.83
0.31
3.2
4.5
21.7
21.3
%
0.07
11
141
60
557
1.17
0.30
3.5
3.1
—
—
—
0
0
38
421
0.85
0.29
5.1
4.1
—
—
—
0
0
102
1038
0.79
0.26
37.2
19.9
136.6
137.1
g/l
0.12
102
1028
18
211
0.82
0.26
3.8
2.3
—
—
—
0
0
8
102
0.77
0.22
2.6
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
26
233
1.15
0.20
2.2
1.7
1.7
1.3
mmol/l
0.94
21
194
10
84
1.21
0.14
1.9
1.9
—
—
—
0
0
8
98
0.80
0.14
2.6
1.7
—
—
—
0
0
86
881
0.89
0.14
4.8
4.0
1.3
1.3
mmol/l
0.21
76
816
66
638
1.09
0.12
3.9
3.1
69.0
49.4
u/l
0.74
59
604
36
342
1.08
0.09
4.4
5.0
1.3
2.9
ug/l
1.07
31
308
11
97
1.15
0.09
13.1
7.0
5.3
5.1
kpa
0.16
11
92
15
136
1.12
0.09
2.7
1.9
—
—
—
0
0
87
885
0.92
0.08
5.2
4.6
6.0
5.9
mmol/l
0.33
79
817
8
77
1.04
0.07
1.9
2.4
8.3
6.0
ug/l
—
8
68
12
110
1.10
0.05
7.1
4.3
26.9
32.2
%
—
7
70
90
909
0.95
0.03
5.5
4.4
1.5
1.5
mmol/l
0.21
81
847
92
913
1.04
0.01
5.3
4.5
4.6
4.7
mmol/l
0.43
85
851
94
934
1.04
0.00
6.0
5.0
2.6
2.8
mmol/l
1.16
86
871
18
182
0.99
0.00
2.1
1.4
—
—
—
0
0
5
53
0.94
0.00
7.0
5.1
24.1
24.9
mmol/l
—
5
53
7
74
0.94
0.00
1.9
1.8
—
—
—
0
0
9
92
0.98
0.00
2.9
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
11.6
—
—
—
0
0
5
54
0.92
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_GLAUCSECDRUG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCSECDRUG | 1.913 [1.39, 2.64] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.14 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 267 females with H7_GLAUCSECDRUG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_GLAUCSECDRUG | 1.552 [1.14, 2.11] | 0.005 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 245 males with H7_GLAUCSECDRUG died.
Mortality risk
Mortality risk for people of age
years, who have H7_GLAUCSECDRUG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.328% |
| 5 | 1.124% | 1.904% |
| 10 | 2.803% | 4.702% |
| 15 | 5.382% | 8.75% |
| 20 | 9.14% | 14.514% |
Relationships between endpoints
↥Index endpoint: H7_GLAUCSECDRUG – Glaucoma secondary to drugs
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data